These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32572590)

  • 1. Current Status of Dyslipidemia Treatment for Stroke Prevention.
    Aradine E; Hou Y; Cronin CA; Chaturvedi S
    Curr Neurol Neurosci Rep; 2020 Jun; 20(8):31. PubMed ID: 32572590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.
    Chang Y; Eom S; Kim M; Song TJ
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering therapy: Guidelines to precision medicine.
    Su X; Cheng Y; Chang D
    Clin Chim Acta; 2021 Mar; 514():66-73. PubMed ID: 33359059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids: a personal view of the past decade.
    Katsiki N; Mikhailidis DP
    Hormones (Athens); 2018 Dec; 17(4):461-478. PubMed ID: 30229482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-Modifying Therapies and Stroke Prevention.
    Hackam DG; Hegele RA
    Curr Neurol Neurosci Rep; 2022 Jul; 22(7):375-382. PubMed ID: 35554824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience).
    Oren O; Kludtke EL; Kopecky SL
    Am J Cardiol; 2019 Dec; 124(11):1669-1673. PubMed ID: 31740018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.
    Page MM; Watts GF
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1505-15. PubMed ID: 26293511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A decade of progress in the management of dyslipidemia].
    Wallemacq C; Paquot N
    Rev Med Liege; 2020 May; 75(5-6):386-391. PubMed ID: 32496685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
    Packard CJ
    Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
    Qamar A; Libby P
    Curr Cardiol Rep; 2019 Jun; 21(8):77. PubMed ID: 31250329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.